Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myeloid, Acute 91Leukemia, Lymphocytic, Chronic, B-Cell 28Myelodysplastic Syndromes 18Recurrence 9Lymphoma, Mantle-Cell 9Leukemia, Biphenotypic, Acute 8Burkitt Lymphoma 8Waldenstrom Macroglobulinemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelomonocytic, Chronic 7Leukemia 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Hematologic Neoplasms 6Lymphoma, Follicular 4Myeloproliferative Disorders 3Multiple Myeloma 3Anemia, Refractory, with Excess of Blasts 3Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, B-Cell 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Blast Crisis 2Venentoclax 1Targeted Therapy 1Sarcoma, Myeloid 1

Interventions

venetoclax 1fludarabine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Venentoclax × venetoclax × 90 days × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡